The LCRP developed a strategy to address multiple issues in lung cancer research over the cancer continuum of care spectrum that will be considered for funding under the LCRP. These Areas of Emphasis are critical gaps in cancer research, care, and/or patient outcomes that, if addressed will lead to reduced suffering from lung cancer and improved quality of life of Service Members, Veterans, and the general public. Simply identifying an Area of Emphasis is not sufficient. Applications must address at least one Area of Emphasis in a way that can lead to, or directly effect, a breakthrough and have a major impact.
• Biology and Etiology o Understand the molecular mechanisms of initiation and progression to lung cancer. o Understand contributors to lung cancer development other than tobacco.
• Prevention o Identify innovative strategies for prevention of the occurrence of lung cancer(s) or subsequent primaries. o Identify innovative strategies for the prevention of recurrence or metastases from lung cancer.
• Detection, Diagnosis, and Surveillance o Improve approaches to screening and early detection of lung cancer. o Identify strategies for prompt detection and/or characterization of progressive disease.
• Treatment and Prognosis o Identify innovative strategies for the treatment of lung cancer, including overcoming resistance. o Develop or optimize biomarkers to assist with therapeutic decision-making. o Enhance the treatment and understanding of brain metastases in lung cancer.
• Health Outcomes and Survivorship o Identify and understand the long-term and cumulative effects of lung cancer and its treatment(s) with respect to the impact of comorbidities on patient care, and also, more broadly, in respect to their effects on patients and their quality of life including, but not limited to, physiological, psychosocial, cognitive, and financial effects.
• Disparities o Advance equity and reduce lung cancer disparities among underserved and underrepresented populations.
The PI must be at or above the level of Assistant Professor (or equivalent). An eligible PI, regardless of ethnicity, nationality, or citizenship status, must be employed by or affiliated with an eligible organization.
The anticipated direct costs budgeted for the entire period of performance for an FY23 LCRP Translational Research Award – Funding Level 1 should not exceed $900,000.
The anticipated direct costs budgeted for the entire period of performance for a FY23 LCRP Translational Research Award – Funding Level 2, Clinical Trial, should not exceed $1.2M. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.